Tudor Investment Corp ET AL Reduces Holdings in Ralliant Corporation $RAL

Tudor Investment Corp ET AL decreased its position in shares of Ralliant Corporation (NYSE:RAL) by 40.6% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 100,000 shares of the company’s stock after selling 68,416 shares during the period. Tudor Investment Corp ET AL owned approximately 0.09% of Ralliant worth $4,373,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in RAL. Cetera Investment Advisers bought a new position in Ralliant during the 2nd quarter valued at about $700,000. Swiss National Bank bought a new stake in Ralliant in the second quarter worth about $16,650,000. DNB Asset Management AS purchased a new position in shares of Ralliant during the second quarter valued at approximately $1,609,000. JPMorgan Chase & Co. purchased a new position in shares of Ralliant during the second quarter valued at approximately $18,494,000. Finally, MAI Capital Management bought a new position in shares of Ralliant during the second quarter valued at approximately $66,000.

Insider Buying and Selling at Ralliant

In other news, Director Kevin E. Bryant purchased 1,250 shares of the company’s stock in a transaction dated Friday, February 6th. The shares were acquired at an average price of $39.97 per share, with a total value of $49,962.50. Following the transaction, the director owned 4,653 shares of the company’s stock, valued at $185,980.41. This represents a 36.73% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Karen M. Bick sold 5,485 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $45.00, for a total value of $246,825.00. Following the transaction, the senior vice president owned 46,756 shares in the company, valued at approximately $2,104,020. This represents a 10.50% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have purchased 8,145 shares of company stock worth $332,233.

Ralliant Stock Performance

Shares of NYSE:RAL opened at $42.73 on Thursday. The firm’s 50 day simple moving average is $46.68 and its 200-day simple moving average is $46.72. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.58 and a current ratio of 0.84. Ralliant Corporation has a one year low of $37.27 and a one year high of $57.02. The firm has a market cap of $4.78 billion and a PE ratio of 21.80.

Ralliant (NYSE:RAL) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $0.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.02. The firm had revenue of $554.60 million during the quarter, compared to analysts’ expectations of $543.04 million. The company’s revenue for the quarter was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, March 23rd. Shareholders of record on Monday, March 9th were issued a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. The ex-dividend date was Monday, March 9th. Ralliant’s dividend payout ratio is currently 10.20%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on RAL. Royal Bank Of Canada reduced their price target on Ralliant from $52.00 to $41.00 and set a “sector perform” rating on the stock in a report on Friday, February 6th. Citigroup cut their price objective on Ralliant from $61.00 to $51.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Vertical Research upgraded Ralliant from a “hold” rating to a “buy” rating and set a $45.00 target price on the stock in a research note on Friday, February 6th. Morgan Stanley reiterated an “overweight” rating and set a $45.00 target price on shares of Ralliant in a research report on Friday, February 6th. Finally, Truist Financial lowered their target price on shares of Ralliant from $62.00 to $49.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Ralliant currently has an average rating of “Hold” and a consensus price target of $50.50.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.